Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Blueprint Medicines's Business Segments
Blueprint Medicines's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 149
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 149 | 100% |
Revenue by Product & Service Category - Q1 FY2025
- Product100%
Revenue by Product & Service Category - Q1 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 149 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Blueprint Medicines
Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing precision therapies for patients with genetically defined diseases. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts. Blueprint Medicines focuses on developing small molecule drugs that target specific genetic abnormalities or pathways associated with diseases.
The company's main area of focus is targeted oncology, with a particular emphasis on developing therapies for patients with gastrointestinal stromal tumors (GIST) and other solid tumor types. Blueprint's lead product, Ayvakit (avapritinib), is a small molecule kinase inhibitor that has been approved by the US FDA for the treatment of patients with GIST who have a specific mutation called PDGFRA exon 18.
Blueprint Medicines has several other programs in development, including BLU-285, a potent inhibitor of KIT and PDGFRA kinase mutations that are resistant to current therapies. The company is also developing an investigational drug, BLU-667, which targets RET, a genetic driver of non-small cell lung cancer and thyroid cancer.
In addition to oncology, Blueprint Medicines is also developing therapies for patients with rare genetic diseases including fibrodysplasia ossificans progressiva (FOP) and achondroplasia, which are both caused by specific genetic mutations.
Notably, Blueprint Medicines has established partnerships with other biopharmaceutical companies, including Roche and CStone Pharmaceuticals, for the development and commercialization of its investigational drug candidates.
Overall, Blueprint Medicines Corporation is a leading biopharmaceutical company that is dedicated to developing precision medicines for patients with genetically defined diseases. Through its innovative approach to drug discovery and development, Blueprint Medicines has the potential to transform the lives of patients living with cancer and rare genetic diseases.
The company's main area of focus is targeted oncology, with a particular emphasis on developing therapies for patients with gastrointestinal stromal tumors (GIST) and other solid tumor types. Blueprint's lead product, Ayvakit (avapritinib), is a small molecule kinase inhibitor that has been approved by the US FDA for the treatment of patients with GIST who have a specific mutation called PDGFRA exon 18.
Blueprint Medicines has several other programs in development, including BLU-285, a potent inhibitor of KIT and PDGFRA kinase mutations that are resistant to current therapies. The company is also developing an investigational drug, BLU-667, which targets RET, a genetic driver of non-small cell lung cancer and thyroid cancer.
In addition to oncology, Blueprint Medicines is also developing therapies for patients with rare genetic diseases including fibrodysplasia ossificans progressiva (FOP) and achondroplasia, which are both caused by specific genetic mutations.
Notably, Blueprint Medicines has established partnerships with other biopharmaceutical companies, including Roche and CStone Pharmaceuticals, for the development and commercialization of its investigational drug candidates.
Overall, Blueprint Medicines Corporation is a leading biopharmaceutical company that is dedicated to developing precision medicines for patients with genetically defined diseases. Through its innovative approach to drug discovery and development, Blueprint Medicines has the potential to transform the lives of patients living with cancer and rare genetic diseases.
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for patients with genetic diseases and cancers. The company has established itself as a leader in precision medicine, emphasizing treatment strategies that are informed by the underlying genetic makeup of diseases. Its comprehensive focus is segmented into two primary areas: Oncology and Genetic Diseases, each addressing distinct therapeutic needs with innovative solutions.
Segments
1. Oncology
The Oncology segment emphasizes the development of therapies targeting specific molecular abnormalities associated with various cancers. Blueprint Medicines is focused on creating kinase inhibitors and other agents that can precisely inhibit the pathways driving the growth of tumor cells. The goal is to provide tailored treatments that enhance efficacy while minimizing the off-target effects that can contribute to adverse events.
2. Genetic Diseases
This segment is aimed at addressing the underlying genetic causes of rare diseases, particularly those that result in significant morbidity. The company prioritizes developing therapies that target specific mutations or pathways associated with these conditions, thereby improving patients overall health and quality of life. Research in this segment often involves understanding the mechanisms of genetic disorders and exploring pharmacological intervention points that can re-establish normal function.
Products and Services
1. AYVAKIT™ (avapritinib)
AYVAKIT is a pivotal therapy in the Oncology segment and serves as a selective kinase inhibitor for patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a specific PDGFRA exon 18 mutation, including the PDGFRA D842V mutation. This medication is designed to target and disrupt the signaling pathways that fuel tumor growth, providing a more effective treatment option for patients with these specific genetic profiles.
2. GAVRETO® (pralsetinib)
GAVRETO is another essential offering from Blueprint Medicines that targets adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). By specifically inhibiting the RET signaling pathway, GAVRETO aims to improve outcomes in patients whose tumors express this biomarker, thereby expanding the therapeutic landscape for lung cancer treatment.
3. BLU-782
This investigational medication represents the company’s commitment to addressing rare genetic disorders. BLU-782 is a highly selective ALK2 inhibitor developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a debilitating condition characterized by the abnormal transformation of soft tissues into bone. By inhibiting ALK2, Blueprint Medicines aims to mitigate the pathological bone formation characteristic of FOP and related diseases.
4. BLU-5937
Focusing on neurological health, BLU-5937 is a selective P2X3 antagonist being explored for its potential to alleviate chronic cough, a condition that affects millions worldwide. Chronic cough can severely diminish quality of life, and this targeted approach seeks to provide relief through modulation of the P2X3 receptor, which plays a critical role in coughing reflexes.
5. Clinical Pipeline
The clinical pipeline at Blueprint Medicines is robust, encompassing several promising drug candidates geared toward various genetic diseases beyond those directly linked to their marketed products. This includes programs targeting hereditary angioedema (HAE), neurofibromatosis type 1 (NF1), and achondroplasia. The ongoing research and development efforts aim to progress these candidates through various stages of clinical trials, with the intent of gaining regulatory approvals in the future.
6. Diagnostic Testing
To complement its therapeutic offerings, Blueprint Medicines provides diagnostic testing services that facilitate the identification of specific genetic mutations in patients diagnosed with GIST and certain cancers. These diagnostic tests enable tailored treatment approaches, allowing healthcare providers to make informed decisions regarding the most appropriate therapeutic options based on individual patient genetics.
Conclusion
Blueprint Medicines Corporations extensive portfolio encapsulates a wide range of innovative products and services tailored toward precision medicine in oncology and genetic diseases. The companys commitment to developing targeted therapies is underscored by its robust clinical pipeline and the integration of diagnostic testing, which together have the potential to significantly impact patient outcomes and enhance overall quality of life in affected populations. As Blueprint continues its mission to transform the treatment landscape, it remains well-positioned to lead advancements in both cancer therapy and the management of genetic disorders.
Segments
1. Oncology
The Oncology segment emphasizes the development of therapies targeting specific molecular abnormalities associated with various cancers. Blueprint Medicines is focused on creating kinase inhibitors and other agents that can precisely inhibit the pathways driving the growth of tumor cells. The goal is to provide tailored treatments that enhance efficacy while minimizing the off-target effects that can contribute to adverse events.
2. Genetic Diseases
This segment is aimed at addressing the underlying genetic causes of rare diseases, particularly those that result in significant morbidity. The company prioritizes developing therapies that target specific mutations or pathways associated with these conditions, thereby improving patients overall health and quality of life. Research in this segment often involves understanding the mechanisms of genetic disorders and exploring pharmacological intervention points that can re-establish normal function.
Products and Services
1. AYVAKIT™ (avapritinib)
AYVAKIT is a pivotal therapy in the Oncology segment and serves as a selective kinase inhibitor for patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a specific PDGFRA exon 18 mutation, including the PDGFRA D842V mutation. This medication is designed to target and disrupt the signaling pathways that fuel tumor growth, providing a more effective treatment option for patients with these specific genetic profiles.
2. GAVRETO® (pralsetinib)
GAVRETO is another essential offering from Blueprint Medicines that targets adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). By specifically inhibiting the RET signaling pathway, GAVRETO aims to improve outcomes in patients whose tumors express this biomarker, thereby expanding the therapeutic landscape for lung cancer treatment.
3. BLU-782
This investigational medication represents the company’s commitment to addressing rare genetic disorders. BLU-782 is a highly selective ALK2 inhibitor developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a debilitating condition characterized by the abnormal transformation of soft tissues into bone. By inhibiting ALK2, Blueprint Medicines aims to mitigate the pathological bone formation characteristic of FOP and related diseases.
4. BLU-5937
Focusing on neurological health, BLU-5937 is a selective P2X3 antagonist being explored for its potential to alleviate chronic cough, a condition that affects millions worldwide. Chronic cough can severely diminish quality of life, and this targeted approach seeks to provide relief through modulation of the P2X3 receptor, which plays a critical role in coughing reflexes.
5. Clinical Pipeline
The clinical pipeline at Blueprint Medicines is robust, encompassing several promising drug candidates geared toward various genetic diseases beyond those directly linked to their marketed products. This includes programs targeting hereditary angioedema (HAE), neurofibromatosis type 1 (NF1), and achondroplasia. The ongoing research and development efforts aim to progress these candidates through various stages of clinical trials, with the intent of gaining regulatory approvals in the future.
6. Diagnostic Testing
To complement its therapeutic offerings, Blueprint Medicines provides diagnostic testing services that facilitate the identification of specific genetic mutations in patients diagnosed with GIST and certain cancers. These diagnostic tests enable tailored treatment approaches, allowing healthcare providers to make informed decisions regarding the most appropriate therapeutic options based on individual patient genetics.
Conclusion
Blueprint Medicines Corporations extensive portfolio encapsulates a wide range of innovative products and services tailored toward precision medicine in oncology and genetic diseases. The companys commitment to developing targeted therapies is underscored by its robust clinical pipeline and the integration of diagnostic testing, which together have the potential to significantly impact patient outcomes and enhance overall quality of life in affected populations. As Blueprint continues its mission to transform the treatment landscape, it remains well-positioned to lead advancements in both cancer therapy and the management of genetic disorders.